Cytokinetics, Incorporated (CYTK)
Total Valuation
Cytokinetics has a market cap or net worth of $7.36 billion. The enterprise value is $7.50 billion.
Market Cap | 7.36B |
Enterprise Value | 7.50B |
Important Dates
The next estimated earnings date is Thursday, May 2, 2024, after market close.
Earnings Date | May 2, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Cytokinetics has 103.01 million shares outstanding. The number of shares has increased by 7.46% in one year.
Shares Outstanding | 103.01M |
Shares Change (YoY) | +7.46% |
Shares Change (QoQ) | +3.15% |
Owned by Insiders (%) | 0.88% |
Owned by Institutions (%) | 113.77% |
Float | 102.08M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 976.84 |
Forward PS | 1,885.85 |
PB Ratio | n/a |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 995.56 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.12
Current Ratio | 6.12 |
Quick Ratio | 6.00 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -17.59 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -65.10% |
Return on Capital (ROIC) | -134.31% |
Revenue Per Employee | $17,801 |
Profits Per Employee | -$1.24M |
Employee Count | 423 |
Asset Turnover | 0.01 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +100.43% in the last 52 weeks. The beta is 0.69, so Cytokinetics's price volatility has been lower than the market average.
Beta (1Y) | 0.69 |
52-Week Price Change | +100.43% |
50-Day Moving Average | 74.32 |
200-Day Moving Average | 47.74 |
Relative Strength Index (RSI) | 51.02 |
Average Volume (30 Days) | 3,584,036 |
Short Selling Information
The latest short interest is 14.80 million, so 14.37% of the outstanding shares have been sold short.
Short Interest | 14.80M |
Short Previous Month | 14.53M |
Short % of Shares Out | 14.37% |
Short % of Float | 14.50% |
Short Ratio (days to cover) | 4.94 |
Income Statement
In the last 12 months, Cytokinetics had revenue of $7.53 million and -$526.24 million in losses. Loss per share was -$5.45.
Revenue | 7.53M |
Gross Profit | 7.53M |
Operating Income | -496.21M |
Pretax Income | -526.24M |
Net Income | -526.24M |
EBITDA | -486.05M |
EBIT | -497.94M |
Loss Per Share | -$5.45 |
Balance Sheet
The company has $614.82 million in cash and $755.77 million in debt, giving a net cash position of -$140.95 million or -$1.37 per share.
Cash & Cash Equivalents | 614.82M |
Total Debt | 755.77M |
Net Cash | -140.95M |
Net Cash Per Share | -$1.37 |
Equity / Book Value | -386.32M |
Book Value Per Share | -3.75 |
Working Capital | 525.37M |
Cash Flow
In the last 12 months, operating cash flow was -$414.33 million and capital expenditures -$1.42 million, giving a free cash flow of -$415.75 million.
Operating Cash Flow | -414.33M |
Capital Expenditures | -1.42M |
Free Cash Flow | -415.75M |
FCF Per Share | -$4.31 |
Margins
Gross margin is 100.00%, with operating and profit margins of -6,589.71% and -6,988.63%.
Gross Margin | 100.00% |
Operating Margin | -6,589.71% |
Pretax Margin | -6,988.63% |
Profit Margin | -6,988.63% |
EBITDA Margin | -6,454.79% |
EBIT Margin | -6,612.72% |
FCF Margin | -5,521.24% |
Dividends & Yields
Cytokinetics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -7.46% |
Shareholder Yield | -7.46% |
Earnings Yield | -7.15% |
FCF Yield | -5.65% |
Analyst Forecast
The average price target for Cytokinetics is $80.53, which is 14.86% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $80.53 |
Price Target Difference | 14.86% |
Analyst Consensus | Strong Buy |
Analyst Count | 15 |
Revenue Growth Forecast (5Y) | 185.69% |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on June 25, 2013. It was a reverse split with a ratio of 1:6.
Last Split Date | Jun 25, 2013 |
Split Type | Reverse |
Split Ratio | 1:6 |
Scores
Cytokinetics has an Altman Z-Score of -1.16 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -1.16 |
Piotroski F-Score | 2 |